Journal of International Psychiatry

【 Abstract 】 Objective To investigate the effect of escitalopram on cardiac function, somatic symptoms, anxiety and depression in patients with acute myocardial infarction. Methods eighty-two patients with acute ST-elevation myocardial infarction with thrombolytic therapy admitted to our hospital from January 2019 to January 2021 were selected and grouped according to random number table method. The somatization symptoms of 41 patients in the control group and 41 patients in the observation group were compared by using escitalopram. Cardiac function: left ventricular ejection fraction (LVEF), left ventricular end diastolic volume index (LVEDVI), left ventricular end systolic volume index (LVESVI); Anxiety and depression: Generalized Anxiety Disorder Scale (GAD-7), patient health Questionnaire depression Self-rating Scale (PHQ-9). Results: After treatment, SSS, GAD-7, PHQ-9 scores, LVEDVI and LVESVI levels in the observation group were lower than those in the control group, while LVEF level was higher than that in the control group, with statistical significance (P<0.05). Conclusion: Escitalopram combined with conventional intravenous thrombolytic therapy can effectively improve cardiac function, reduce somatization symptoms and anxiety and depression in patients with acute ST elevation myocardial infarction.

【 Key words 】 Escitalopram; Acute ST elevation myocardial infarction; Intravenous thrombolysis; Depressed mood